Lets be clear here: CBD is not a CB1 or CB2 agonist (or antagonist, or anything else). It is active at the serotonin-1a autoreceptor (like buspirone) as a partial agonist and then only at dosages that are infeasibly expensive at current market pricing. An adult human typically requires multiple 0.3 to 0.6 gram (that's 600 milligram) doses per day to reach a physiologically active level.
Dosing and pricing it like THC is simply placebo. It is not THC. This study is based off obviously false premises.
Dosing and pricing it like THC is simply placebo. It is not THC. This study is based off obviously false premises.